Healthcare is catching the rotation out of AI. Josh Brown's list includes two names that can benefit

Healthcare gained 2.4% Wednesday and 1.8% Thursday as investors rotated from technology after a hotter-than-expected CPI report; XLV rose 5.4% over the five sessions ended Oct. 15, and healthcare was up 12.4% year to date through Oct. 14. Waters is up 57% from its March low after Q2 revenue of $1.65B and adjusted EPS of $3.05 beat expectations; management raised full-year organic growth guidance to 7%-9% and adjusted EPS guidance to $14.45-$14.65. Thermo Fisher is up 20.5% year to date after Q2 revenue rose 10% and adjusted EPS rose 13%; management raised full-year guidance, and the company reports Q3 on Oct. 21.

Analysis

The key signal is a change in what investors are paying for: healthcare’s relative appeal may be shifting from valuation recovery to earnings revisions and diversification from AI-linked returns. That can support life-science tools beyond a short-lived defensive rotation, but recent leadership and sharp rebounds make near-term positioning vulnerable to a crowded-trade unwind. The CPI-driven sector move is not, by itself, evidence of durable incremental demand.

For TMO, Wednesday’s report is the immediate test: the market has rewarded improving execution and order commentary, so merely meeting estimates may not extend the rerating if orders do not convert into revenue or guidance lacks follow-through. A miss or weaker conversion could unwind the breakout quickly. For WAT, the November report is the next company-specific catalyst; the acquired BD business adds integration and comparability risk, so verify organic growth and contribution from each business rather than relying on consolidated beats. WAT’s recovery also leaves less room for execution slippage.

Second order: sustained lab-spending recovery would benefit competing instrument and research-services providers such as Danaher and Agilent, while a slowdown in pharma/biotech budgets would pressure the same ecosystem. Becton, Dickinson and Solventum are relevant to portfolio changes referenced in the article, but no earnings or valuation conclusion follows from those transactions alone. Contrarian risk: investors may be extrapolating a few weeks of rotation and upward revisions; if tech stabilizes and healthcare revisions flatten, relative flows can reverse even without company-specific deterioration.

Key Decisions for Investors

• TMO: Treat Wednesday’s release as a catalyst, not a reason to chase ahead of results. Consider initiating or adding only if revenue and order conversion support guidance and the stock holds above $650 on a closing basis; a close below $650 would invalidate the near-term breakout setup. For a longer-horizon position, a weekly close below $600 is a more meaningful trend warning.
• WAT: Prefer a conditional breakout entry only on a decisive move above $455 with confirmation from Nov. 3 results. Use a closing stop near $420 for a tactical position; for a longer-term thesis, a weekly close below $390 would materially weaken it. Verify organic growth and acquired-business performance before treating consolidated growth as evidence of broad-based acceleration.
• Avoid making a broad healthcare overweight solely from the recent sector rotation. Reassess over the next 1–3 months against estimate revisions and relative performance versus the S&P 500; flatten or hedge the tilt if revisions stall and healthcare loses relative strength.
• Watch TMO order-to-revenue conversion, full-year guidance, and WAT organic growth at the next reports. Downward guidance revisions or evidence of weaker pharma/biotech spending would falsify the earnings-led tools thesis; sustained revisions and breakouts holding their stated levels would support it.